BCRX
BioCryst Pharmaceuticals Inc
8.20$
+0.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.9% | -9.5% | -57.9% | -1.3% | 7.0% | -4.0% | -18.9% | 25.3% | 26.1% | 67.9% | -39.7% | 47.8% | 38.3% | |
| 0.5% | 0.5% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 1.0% | 0.7% | 0.2% | 0.6% | |
| 14.2% | 17.7% | 14.7% | 12.0% | 14.7% | 16.2% | 14.7% | 13.0% | 11.7% | 17.8% | 10.2% | 6.7% | 13.0% | |
| -18.7% | 19.4% | -52.3% | -16.7% | -7.8% | -8.6% | -42.7% | 1.5% | -0.9% | 1.0% | -45.7% | -1.4% | -7.6% | |
| 1.1% | 0.6% | 0.3% | 0.1% | 0.1% | 0.5% | 0.1% | 0.1% | 0.8% | 0.2% | 0.3% | 0.1% | 0.3% | |
| 26.7% | -30.5% | 31.0% | -2.2% | 7.3% | 13.5% | 18.6% | 17.8% | 8.5% | -20.5% | -171.8% | -50.5% | -47.7% | |
| – | -2.3% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -0.5% | -0.3% | -0.4% | -42.9% | -29.4% | -45.4% | 255.5% | -0.2% | 17.8% | |
| 1.4% | -3.4% | -1.1% | -1.8% | 1.1% | -3.1% | 0.4% | -45.1% | -36.9% | -49.7% | 264.0% | -5.1% | 15.0% | |
| 5.4% | -42.9% | -28.4% | -5.4% | 16.1% | 5.5% | 0.4% | -10.4% | -2.4% | -20.4% | 52.8% | -7.8% | -2.3% | |
| -24.1% | -10.1% | -58.1% | -1.4% | 7.0% | -4.5% | -19.0% | 25.2% | 25.3% | 67.7% | -40.0% | 47.7% | 38.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.